



10 January 2018

Cancellation of Unlisted Options

Zelda Therapeutics Limited (ASX: ZLD, “the Company” or “Zelda”) wishes to advise the cancellation of the following unlisted options, issued under an Employee Share Option Plan (ESOP), as vesting conditions were not met:

Number	Details of Cancelled ESOP Options
1,500,000	Exercise price of \$0.04, vesting on 6 February 2019, expiring on 6 February 2020.

The Company’s current capital structure is as follows:

Number	Class
530,467,090	Ordinary shares
224,374,844	Ordinary shares held in escrow for 24 months from reinstatement to official quotation
40,000,000	Unlisted options exercisable at \$0.03125 on or before 17 November 2021 held in escrow for 24 months from reinstatement to official quotation
2,000,000	Unlisted options exercisable at \$0.04 on or before 6 February 2020.
4,500,000	Unlisted options exercisable at \$0.04 on or before 6 February 2020 and subject to vesting conditions.

ENDS

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics (“Zelda”) is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A human clinical trial programme focused on insomnia, autism and eczema with activities in Australia and Chile.
- A pre-clinical research programme examining the effect of cannabinoids in breast, brain and pancreatic cancer. It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.

